Regulatory Approval Delays or Failure: Anbio Biotechnology operates in a highly regulated environment. Obtaining necessary approvals from health authorities for its diagnostic products or therapeutic candidates is a complex, costly, and lengthy process. Delays or outright failure to secure these approvals would significantly impact product launch schedules, revenue projections, and overall business viability.

Clinical Trial Outcomes and Efficacy Concerns: The success of Anbio's pipeline products depends on favorable results from preclinical and clinical trials. These trials are expensive and time-consuming, and their outcomes are inherently uncertain. Products may fail to demonstrate sufficient safety or efficacy, encounter unexpected adverse events, or not meet primary endpoints, leading to termination of development and substantial financial losses.

Intense Competitive Landscape: The biotechnology and diagnostics sectors are characterized by fierce competition from established pharmaceutical companies, other biotech firms, and academic institutions. Competitors may develop superior or more cost-effective products, gain earlier regulatory approvals, or achieve broader market adoption. Anbio's ability to maintain or grow market share could be challenged by this dynamic environment, potentially eroding its pricing power and profitability.